Jonathan Gould spent roughly three years at the OCC, from 2018 to 2021, and has focused heavily on financial services ...
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback